CROSS-DOMAIN
TECHNOLOGY LEADERSHIP
FOR CLINICALLY CREDIBLE
HEALTH INNOVATION.
Dr. Mitchell Frye, PhD, AuD, MBA, brings together translational science, clinical operations, and commercial strategy to help health-tech, med-tech, and AI-enabled healthcare organizations move from technical promise to operationally useful, clinically credible scale.
SCIENTIFIC RIGOR • CLINICAL OPERATIONS • COMMERCIAL STRATEGY • TRANSLATIONAL SCIENCE • HEALTH TECH LEADERSHIP •
The Three-Domain Overlap
Built at the intersection of science, care delivery, and commercial strategy.
For regulated health-tech, med-tech, and AI-enabled healthcare organizations.
EVIDENCE DISCIPLINE • WORKFLOW INTEGRATION • MARKET LOGIC •
Operating Logic
01 / Scientific rigor
Evidence Discipline
Converts biomedical complexity into credible validation logic, grounded in NIH-funded device research, sensory neuroscience, neuroimmunology, and translational science.
02 / Clinical Operations
Workflow Integration
Grounds technology strategy in real care delivery workflows, multidisciplinary operations, regulated environments, and implementation constraints across complex healthcare systems.
03 / Commercial Strategy
Market
Logic
Links scientific and operational credibility to business model design, capital efficiency, stakeholder adoption, and go-to-market strategy for health-tech, med-tech, and AI-enabled healthcare.
Selected Strategic Work
01 / AI-Enabled Care Strategy
AI-First Neurorehab Risk & Recovery
A workflow-native clinical AI orchestration concept for medically complex neurorehab, focused on earlier risk visibility, recovery coordination, and enterprise care-transition execution.
02 / Health-Tech Capital Strategy
Tempus AI | Capital & Profitability
A finance-focused executive case study examining Tempus AI’s growth model, capital intensity, reinvestment logic, margin trajectory, and path to sustainable enterprise-scale profitability.